Your browser is no longer supported. Please, upgrade your browser.
EBS [NYSE]
Emergent BioSolutions Inc.
Index- P/E9.17 EPS (ttm)5.50 Insider Own0.70% Shs Outstand53.60M Perf Week-2.27%
Market Cap2.75B Forward P/E9.74 EPS next Y5.17 Insider Trans-0.82% Shs Float48.63M Perf Month-11.78%
Income299.20M PEG1.00 EPS next Q2.35 Inst Own86.60% Short Float6.72% Perf Quarter-22.59%
Sales1.71B P/S1.61 EPS this Y445.20% Inst Trans0.52% Short Ratio8.03 Perf Half Y-23.18%
Book/sh28.80 P/B1.75 EPS next Y-31.89% ROA10.60% Target Price85.71 Perf Year-49.02%
Cash/sh8.21 P/C6.14 EPS next 5Y9.20% ROE20.80% 52W Range49.35 - 127.20 Perf YTD-43.74%
Dividend- P/FCF22.73 EPS past 5Y24.00% ROI14.30% 52W High-60.37% Beta0.98
Dividend %- Quick Ratio2.10 Sales past 5Y26.00% Gross Margin63.30% 52W Low2.15% ATR1.73
Employees2200 Current Ratio3.10 Sales Q/Q0.70% Oper. Margin25.10% RSI (14)34.40 Volatility2.42% 3.66%
OptionableYes Debt/Eq0.55 EPS Q/Q-95.10% Profit Margin17.50% Rel Volume0.95 Prev Close50.69
ShortableYes LT Debt/Eq0.53 EarningsJul 29 AMC Payout0.00% Avg Volume406.80K Price50.41
Recom2.40 SMA20-4.46% SMA50-12.71% SMA200-32.04% Volume386,142 Change-0.55%
May-05-21Downgrade Argus Buy → Hold
Apr-07-21Initiated The Benchmark Company Buy $150
Feb-24-21Upgrade Chardan Capital Markets Neutral → Buy $112
Feb-19-21Downgrade Chardan Capital Markets Buy → Neutral $112
Jan-08-21Downgrade Wells Fargo Overweight → Equal Weight $110
Sep-14-20Resumed JP Morgan Neutral $103
Jul-31-20Reiterated Chardan Capital Markets Buy $86 → $112
Sep-12-19Initiated Guggenheim Buy
Sep-04-19Upgrade Wells Fargo Market Perform → Outperform
Nov-02-18Upgrade Goldman Neutral → Buy
Aug-03-18Reiterated Chardan Capital Markets Buy $53 → $57
Jun-13-18Initiated Argus Buy $62
Apr-25-18Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18Initiated Goldman Neutral
Jan-16-18Reiterated Chardan Capital Markets Buy $47 → $53
Jun-28-16Reiterated Singular Research Buy $44 → $40
Apr-15-16Initiated Chardan Capital Markets Buy $47
Mar-28-16Initiated Singular Research Buy $44
Feb-19-16Initiated Wells Fargo Outperform
May-15-14Initiated Summer Street Research Buy $35
Oct-18-21 06:30AM  
Oct-15-21 06:30AM  
Oct-12-21 09:24AM  
Sep-28-21 05:00AM  
Sep-23-21 08:49AM  
Sep-21-21 01:23PM  
Sep-20-21 02:10AM  
Sep-17-21 10:06AM  
Sep-15-21 10:53AM  
Sep-14-21 08:32AM  
08:00AM  
02:26AM  
Aug-31-21 08:00AM  
Aug-25-21 08:59AM  
07:05AM  
06:30AM  
Aug-23-21 04:05PM  
Aug-21-21 02:40PM  
Aug-19-21 08:57PM  
Aug-06-21 06:36PM  
05:55PM  
Aug-02-21 09:06AM  
Jul-30-21 06:51PM  
10:42AM  
10:18AM  
10:04AM  
09:54AM  
05:02AM  
Jul-29-21 07:25PM  
06:30PM  
04:05PM  
11:01AM  
10:16AM  
07:25AM  
12:25AM  
Jul-28-21 11:24PM  
Jul-26-21 09:01AM  
Jul-25-21 04:21AM  
Jul-22-21 03:03PM  
Jul-20-21 07:25AM  
Jul-15-21 06:30AM  
Jul-07-21 09:39AM  
Jul-03-21 08:02AM  
Jul-02-21 04:11PM  
Jun-29-21 07:01AM  
Jun-24-21 09:19AM  
Jun-23-21 10:52AM  
09:06AM  
Jun-22-21 05:29AM  
Jun-21-21 05:01PM  
03:30PM  
02:00PM  
01:20PM  
12:34PM  
09:45AM  
09:10AM  
05:40AM  
01:00AM  
Jun-20-21 12:30PM  
11:35AM  
11:10AM  
10:42AM  
Jun-19-21 08:27AM  
Jun-18-21 08:20PM  
08:02PM  
07:15PM  
12:00PM  
10:55AM  
10:11AM  
10:00AM  
Jun-17-21 07:00PM  
06:40PM  
01:40PM  
11:20AM  
11:00AM  
11:00AM  
10:54AM  
10:05AM  
09:45AM  
09:06AM  
06:30AM  
06:12AM  
Jun-16-21 10:26PM  
10:26PM  
10:00PM  
06:47PM  
05:15PM  
04:29PM  
03:00PM  
02:00PM  
01:10PM  
12:39PM  
10:53AM  
10:45AM  
10:00AM  
05:23AM  
Jun-15-21 11:06PM  
06:26PM  
04:51PM  
04:01PM  
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zoon Kathryn CDirectorMay 25Sale56.483,139177,29114,377May 27 04:37 PM
SULLIVAN LOUIS WDirectorMay 10Option Exercise18.6410,305192,08543,063May 11 04:18 PM
Bailey SueDirectorMar 04Sale92.378,168754,47824,427Mar 08 06:30 PM
Havey AdamEVP, Business OperationsMar 01Option Exercise40.9037,2791,524,81258,335Mar 03 06:07 PM
Havey AdamEVP, Business OperationsMar 01Sale99.3037,2793,701,64738,190Mar 03 06:07 PM
Kramer RobertPresident and CEOFeb 08Option Exercise30.7945,3971,397,961171,607Feb 09 05:23 PM
Kramer RobertPresident and CEOFeb 08Sale120.0345,3975,449,002139,210Feb 09 05:23 PM
Kramer RobertPresident and CEOJan 21Option Exercise26.4521,900579,255161,110Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 21Sale110.0321,9002,409,657139,210Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 20Option Exercise26.452,23259,036141,442Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 20Sale110.002,232245,520139,210Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 15Option Exercise25.6219,026487,446158,236Jan 19 04:28 PM
Kramer RobertPresident and CEOJan 15Sale106.0119,0262,016,901139,210Jan 19 04:28 PM
El-Hibri FuadChairmanNov 10Option Exercise26.4519,391512,8921,143,379Nov 12 06:30 PM
El-Hibri FuadChairmanNov 10Sale88.2119,3911,710,4801,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Option Exercise26.4520,000529,0001,143,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Sale95.2620,0001,905,2001,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 03Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 03Sale90.7420,0001,814,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Sale90.4420,0001,808,8001,123,988Nov 04 08:53 PM